Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





SARS-CoV-2 Variant Test Breakthrough to Improve Tracking and Understanding of Emerging COVID-19 Mutations

By LabMedica International staff writers
Posted on 15 Jun 2021
A new highly reliable COVID-19 variant test can accurately identify known SARS-CoV-2 variants and aid in the discovery of novel variants.

Aventus Health (Orlando, FL, USA) has launched its new COVID-19 Variant Test designed to reliably identify known SARS-CoV-2 variants and the discovery of novel variants. More...
Aventus’ COVID-19 Variant Test was developed through an innovative application of its Next-Generation Sequencing (NGS) technology and the cutting-edge, laboratory-developed assay that together break down the sequence of base pairs that constitute the genetic makeup of the various strains of corona virus. The result is a reliable test result that can advance the study, tracking and understanding of emerging COVID-19 variants and their potential impact on public health.

Aventus offers a suite of COVID-19 testing services and will now include reflex testing-to-NGS on all Aventus’ RT-PCR patient tests that return a positive result in order to identify currently known variants as well as those yet to be discovered. There is no additional cost or special instructions for individuals using Aventus’ tests.

According to Aventus’ Medical Director, Michelle Taylor, MD, variant testing is complicated and not widely available because it requires scientists use a process called genomic sequencing, which requires advanced and expensive technology and diagnostic expertise. “The instruments Aventus uses are manufactured for the highest sensitivity genetic sequencing capabilities on the market,” Dr. Taylor noted. “They are critical to our mission of helping healthcare providers leverage innovations in genomics and diagnostics to deliver affordable and effective personalized and precision medicine. Addressing the need for COVID-19 and variant testing and diagnostics is a natural fit for us.”

“This is a breakthrough in healthcare that will greatly aid the general public in better understanding the different strains of COVID-19. It will allow us to know what strain an individual has and even get ahead of the curve on any new strains that may develop,” added Oliver Dawoud, Aventus CEO.


Related Links:
Aventus Health


Platinum Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 Antibody Test
SARS-CoV-2 UTAB FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.